Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.
Ontology highlight
ABSTRACT: l-asparaginase, an enzyme originally derived from Escherichia coli, represents a major drug in the treatment of acute lymphoblastic leukemia. However, the occurrence of major adverse effects often leads to early withdrawal of the enzyme. Main side effects include immune-allergic reactions, coagulopathy, pancreatitis and hepatic disorders. Novel asparaginase formulations and alternative sources have been developed to address this issue, but the results were not totally satisfactory. l-asparaginase loaded red blood cells (RBCs; GRASPA) represent a new asparaginase presentation with reduced immunological adverse reactions. RBCs protect l-asparaginase, enhance its half-life and reduce the occurrence of adverse events. We reviewed the history, biology and clinical experiences with l-aspa
SUBMITTER: Thomas X
PROVIDER: S-EPMC6172001 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature
ACCESS DATA